SHB 1238
In CommitteeHouse
Rare diseases adv. council
Creating an advisory council on rare diseases.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill creates a 12-member advisory council to help the state improve care and support for people with rare diseases—conditions affecting fewer than 200,000 people in the U.S. The council, housed at the University of Washington, will advise health officials, coordinate research and outreach, and recommend policy changes and a new public resource website.
- Establishes an advisory council on rare diseases within the University of Washington School of Medicine to advise the Secretary of Health on research, diagnosis, treatment, and education related to rare diseases.
- The council includes 12 voting members appointed by the Secretary of Health: 4 clinicians/researchers, 4 patient advocates (including patients, caregivers, and foundation reps), 1 representative from the Department of Health’s children and youth with special health care needs program, 1 from the Health Care Authority, and 2 from the life sciences industry.
- Council members must represent both east and west of the Cascade Mountains, serve 3-year terms, and meet at least quarterly after their first meeting (which must occur within 6 months of the bill’s effective date).
- The council will produce a biennial report to the governor and legislature starting December 1, 2026, detailing its work and recommending changes to laws, programs, or the council itself.
- The council will identify strategies to improve diagnosis and treatment, advise on public education efforts, and recommend creating a publicly accessible website to centralize rare disease resources for patients and providers in Washington.
- The council serves only in an advisory capacity and cannot override local health jurisdictions during disease outbreaks.
Who is affected
- Patients with rare diseases and their families/caregivers — Patients living with rare diseases and their families/caregivers will gain access to improved coordination of care, better-informed providers, and a centralized resource website; may benefit from faster diagnosis and more targeted support services.
- Healthcare providers and researchers specializing in rare diseases — Clinicians, researchers, nurses, genetic counselors, and social workers who treat or study rare diseases will have a formal advisory role in shaping state policy and research priorities.
- State health agencies (Department of Health, Health Care Authority) — State agencies (Department of Health and Health Care Authority) will receive expert advice to improve programs for children and adults with rare diseases and inform budget and policy decisions.
- Life sciences industry stakeholders — Life sciences companies developing treatments for rare diseases will have a voice in state-level research and policy discussions and may help guide regulatory or funding priorities.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Direct inclusion of patients, caregivers, and patient advocates (4 of 12 voting members) ensures lived experience shapes state-level recommendations, improving alignment between policy and real-world patient needs—especially for diagnosis delays and care coordination.
HealthcarePeopleRef: Sec. 2(2)(b)Mandating education and outreach to medical providers, schools, and public health districts can reduce misdiagnosis and improve early intervention—benefiting families of children with rare diseases, especially in underserved regions.
EducationPeopleRef: Sec. 3(1)(d)–(e)A centralized, publicly accessible resource website for rare diseases would directly help patients and caregivers navigate fragmented care, reduce diagnostic odysseys, and improve health literacy—particularly valuable for rural residents with limited specialist access.
HealthcarePeopleRef: Sec. 3(1)(f)Geographic and term limits (east/west Cascade representation, 3-year terms with rotation) promote balanced stakeholder input and prevent institutional capture, supporting equitable access across Washington’s diverse regions.
Local GovernmentPeopleRef: Sec. 2(3) & Sec. 2(4)Biennial reporting to the governor and legislature creates accountability and a formal channel for evidence-based policy improvements—potentially leading to better-funded rare disease programs over time.
HealthcarePeopleRef: Sec. 3(2)
Potential Concerns (5)
The two life sciences industry representatives on the 12-member council may disproportionately influence research and policy priorities toward commercially viable (often high-cost) therapeutics, potentially marginalizing patient-centered needs like diagnostics, palliative care, or non-commercial research.
HealthcarePeopleRef: Sec. 2(2)(e)The bill relies on the University of Washington to provide staff support (including physician leadership) and does not guarantee dedicated state funding, risking inconsistent capacity and potential strain on university resources—especially if legislative appropriations are insufficient or inconsistent over time.
Local GovernmentLean peopleRef: Sec. 2(6) & Fiscal ImpactWhile the council explicitly cannot override local health jurisdictions during outbreaks, its advisory role may create ambiguity or delay in rare disease-related public health responses if local officials seek its input before acting, potentially slowing emergency coordination for conditions with infectious components.
Public SafetyPeopleRef: Sec. 3(3)The requirement for clinicians and researchers to be “specializing in rare diseases” may exclude many rural or generalist providers who actually serve the majority of Washington’s rare disease patients, limiting frontline perspectives and potentially reinforcing urban-centric care models.
HealthcareLean peopleRef: Sec. 2(2)(a)–(e)Creation of a public website is recommended but not funded or mandated with timelines or performance metrics, making its implementation highly dependent on future legislative appropriation and agency priorities—risking a symbolic but under-resourced outcome.
Public SafetyLean peopleRef: Sec. 3(1)(f)
Who Is Most Affected
Patients and families benefit most directly—especially those with undiagnosed or long-diagnosed rare conditions. Improved provider education and a centralized resource site can reduce diagnostic delays and improve quality of life. However, those in rural areas may still face access barriers if the council’s work doesn’t translate into local care infrastructure.
Clinicians and researchers gain formal influence over state policy and research priorities, potentially increasing collaboration and funding. However, those without existing rare disease expertise may be excluded, and academic institutions may face added administrative burdens without dedicated staffing funds.
State agencies (DOH and HCA) gain expert input to improve program design and budget requests, especially for children and youth with special health care needs. However, the council’s advisory nature means agencies retain full discretion—so influence may be symbolic without binding power.
Life sciences companies gain direct access to state policy discussions and may help shape research agendas and regulatory pathways. However, the two industry seats are balanced by equal patient/advocate representation, limiting unilateral influence—though industry may still benefit more from commercialization-focused recommendations.